Genoway (ALGEN) - Net Assets
Based on the latest financial reports, Genoway (ALGEN) has net assets worth €18.39 Million EUR (≈ $21.50 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€38.82 Million ≈ $45.39 Million USD) and total liabilities (€20.43 Million ≈ $23.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Genoway asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.39 Million |
| % of Total Assets | 47.37% |
| Annual Growth Rate | 12.08% |
| 5-Year Change | 106.45% |
| 10-Year Change | 297.14% |
| Growth Volatility | 958.84 |
Genoway - Net Assets Trend (2004–2024)
This chart illustrates how Genoway's net assets have evolved over time, based on quarterly financial data. Also explore how large is Genoway's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Genoway (2004–2024)
The table below shows the annual net assets of Genoway from 2004 to 2024. For live valuation and market cap data, see ALGEN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €18.57 Million ≈ $21.72 Million |
+6.86% |
| 2023-12-31 | €17.38 Million ≈ $20.32 Million |
+7.53% |
| 2022-12-31 | €16.17 Million ≈ $18.90 Million |
+11.05% |
| 2021-12-31 | €14.56 Million ≈ $17.02 Million |
+61.79% |
| 2020-12-31 | €9.00 Million ≈ $10.52 Million |
+31.49% |
| 2019-12-31 | €6.84 Million ≈ $8.00 Million |
-13.28% |
| 2018-12-31 | €7.89 Million ≈ $9.22 Million |
+9.73% |
| 2017-12-31 | €7.19 Million ≈ $8.41 Million |
+36.72% |
| 2016-12-31 | €5.26 Million ≈ $6.15 Million |
+12.45% |
| 2015-12-31 | €4.68 Million ≈ $5.47 Million |
-9.11% |
| 2014-12-31 | €5.15 Million ≈ $6.02 Million |
+0.84% |
| 2013-12-31 | €5.10 Million ≈ $5.97 Million |
+5.49% |
| 2012-12-31 | €4.84 Million ≈ $5.66 Million |
-7.53% |
| 2011-12-31 | €5.23 Million ≈ $6.12 Million |
+13.81% |
| 2010-12-31 | €4.60 Million ≈ $5.37 Million |
+20.21% |
| 2009-12-31 | €3.82 Million ≈ $4.47 Million |
+12.50% |
| 2008-12-31 | €3.40 Million ≈ $3.97 Million |
-25.53% |
| 2007-12-31 | €4.56 Million ≈ $5.34 Million |
+4288.46% |
| 2006-12-31 | €104.00K ≈ $121.59K |
+106.63% |
| 2005-12-31 | €-1.57 Million ≈ $-1.83 Million |
-182.71% |
| 2004-12-31 | €1.90 Million ≈ $2.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genoway's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 260116700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.60 Million | 14.00% |
| Common Stock | €5.69 Million | 30.63% |
| Other Comprehensive Income | €1.17 Million | 6.32% |
| Other Components | €9.11 Million | 49.05% |
| Total Equity | €18.57 Million | 100.00% |
Genoway Competitors by Market Cap
The table below lists competitors of Genoway ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Salomon A Angel Ltd
TA:ANGL
|
$30.12 Million |
|
Urban One Inc Class D
NASDAQ:UONEK
|
$30.13 Million |
|
Finbond Group Ltd
JSE:FGL
|
$30.15 Million |
|
Chariot Oil & Gas Limited
F:C62
|
$30.16 Million |
|
Paru Co. Ltd
KQ:043200
|
$30.11 Million |
|
Omax Autos Limited
NSE:OMAXAUTO
|
$30.09 Million |
|
Dental Corporation Public Company Limited
BK:D
|
$30.08 Million |
|
Dongkuk Refractories & Steel Co. Ltd
KQ:075970
|
$30.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genoway's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,382,857 to 18,574,866, a change of 1,192,009 (6.9%).
- Net income of 1,831,000 contributed positively to equity growth.
- Share repurchases of 101,544 reduced equity.
- New share issuances of 125,400 increased equity.
- Other comprehensive income decreased equity by 662,580.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.83 Million | +9.86% |
| Share Repurchases | €101.54K | -0.55% |
| Share Issuances | €125.40K | +0.68% |
| Other Comprehensive Income | €-662.58K | -3.57% |
| Other Changes | €-267.00 | -0.0% |
| Total Change | €- | 6.86% |
Book Value vs Market Value Analysis
This analysis compares Genoway's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.69x to 1.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €0.65 | €2.39 | x |
| 2010-12-31 | €0.78 | €2.39 | x |
| 2011-12-31 | €0.89 | €2.39 | x |
| 2012-12-31 | €0.82 | €2.39 | x |
| 2013-12-31 | €0.85 | €2.39 | x |
| 2014-12-31 | €0.87 | €2.39 | x |
| 2015-12-31 | €0.79 | €2.39 | x |
| 2016-12-31 | €0.88 | €2.39 | x |
| 2017-12-31 | €1.21 | €2.39 | x |
| 2018-12-31 | €1.34 | €2.39 | x |
| 2019-12-31 | €1.17 | €2.39 | x |
| 2020-12-31 | €1.33 | €2.39 | x |
| 2021-12-31 | €1.67 | €2.39 | x |
| 2022-12-31 | €1.83 | €2.39 | x |
| 2023-12-31 | €1.93 | €2.39 | x |
| 2024-12-31 | €1.96 | €2.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genoway utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.86%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.30%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.71x
- Recent ROE (9.86%) is above the historical average (4.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 3.05% | 1.76% | 0.59x | 2.92x | €-265.70K |
| 2010 | 12.21% | 7.64% | 0.64x | 2.49x | €101.43K |
| 2011 | 9.60% | 6.49% | 0.70x | 2.10x | €-20.84K |
| 2012 | -7.28% | -4.03% | 0.83x | 2.18x | €-835.86K |
| 2013 | 5.23% | 2.65% | 1.01x | 1.95x | €-238.45K |
| 2014 | 0.52% | 0.28% | 0.93x | 2.02x | €-488.01K |
| 2015 | 0.82% | 0.38% | 0.94x | 2.30x | €-429.33K |
| 2016 | 11.07% | 5.05% | 0.99x | 2.22x | €56.29K |
| 2017 | 26.86% | 14.67% | 0.77x | 2.39x | €1.21 Million |
| 2018 | 7.25% | 3.82% | 0.76x | 2.50x | €-217.37K |
| 2019 | -15.15% | -7.26% | 0.75x | 2.80x | €-1.72 Million |
| 2020 | -7.64% | -6.24% | 0.40x | 3.06x | €-1.59 Million |
| 2021 | -2.19% | -2.30% | 0.43x | 2.21x | €-1.79 Million |
| 2022 | 4.81% | 4.56% | 0.52x | 2.04x | €-838.85K |
| 2023 | 9.02% | 7.82% | 0.63x | 1.83x | €-170.71K |
| 2024 | 9.86% | 8.30% | 0.69x | 1.71x | €-26.49K |
Industry Comparison
This section compares Genoway's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,005,943
- Average return on equity (ROE) among peers: -115.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genoway (ALGEN) | €18.39 Million | 3.05% | 1.11x | $30.11 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $123.48 Million |
| Abivax SA (ABVX) | $11.78 Million | -260.03% | 3.39x | $6.97 Billion |
| Adocia (ADOC) | $45.85 Million | 16.61% | 0.53x | $111.73 Million |
| Aelis Farma SA (AELIS) | $1.20 Million | -263.37% | 5.00x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $6.83 Million | -373.49% | 2.98x | $1.03 Million |
| Cellectis (ALCLS) | $450.27 Million | -17.48% | 0.11x | $282.27 Million |
| Advicenne (ALDVI) | $16.92 Million | -83.89% | 0.35x | $21.67 Million |
| Integragen (ALINT) | $2.19 Million | 0.70% | 3.39x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more